BSE · 526139
Transgene Biotek Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-0 Cr — a -650% net margin, versus -920% the period before.
Shareholding
As of 2026-09-30
- Promoter23.64%
- Public76.36%
13,775 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.29× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #349 of 552 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| National Stock Exchange Of India Ltd. | ₹4,42,765 Cr | 49.53 | 13.79 | 22.8% | 64.54% |
| Adani Ports & Special Economic Zone Ltd. | ₹4,31,301 Cr | 31.19 | 4.17 | 13.33% | 31.98% |
| Eternal Limited | ₹3,26,037 Cr | 662.45 | 10.41 | 1.58% | 0.63% |
| BSE Limited | ₹1,42,841 Cr | 50.45 | 21.41 | 37.42% | 52.03% |
| Vedanta Aluminium Metal Limited | ₹1,36,453 Cr | 11.36 | 5.92 | 80.07% | 23.43% |
| GAIL (India) Ltd. | ₹1,08,601 Cr | 11 | 1.22 | 8.51% | 6.67% |
| One 97 Communications Ltd. | ₹1,08,337 Cr | 129.23 | 6.53 | 5.15% | 8.95% |
| Meesho Limited | ₹1,04,040 Cr | — | 24.72 | -21.93% | -6.19% |
| GMR Airports Limited | ₹93,038 Cr | 155.84 | 0 | -25.64% | 3.13% |
| Multi Commodity Exchange of India Ltd. | ₹82,388 Cr | 53.44 | 28.91 | 46.75% | 58.61% |
| Transgene Biotek Ltd.(this company) | ₹18 Cr | — | 2.19 | -19.73% | -766.67% |
AI analysis
AI-generated · google/gemini-2.5-flashTransgene Biotek Ltd. (526139) has a market capitalization of Rs 22 Cr. The company reported a negative EPS of 0 and a negative return on equity (ROE) of -19.73%. Its debt-to-equity ratio stands at 1.38.
Positives
- +Promoter shareholding is not pledged, with promoter pledge at 0%.
Negatives
- −The company consistently reported negative net profits across all available quarterly data, such as -Rs 0.46 Cr for Mar 2026.
- −The profit margin is significantly negative at -825%.
- −Return on equity (ROE) is negative at -19.73%.
- −Return on capital employed (ROCE) is negative at -2.32%.
- −The debt-to-equity ratio is high at 1.38.
- −The company is under GSM (Graded Surveillance Measure) Stage 0.
Financial Performance
Transgene Biotek Ltd. reported quarterly revenues of Rs 0.05 Cr for the periods ending Jun 2025, Sept 2025, and Dec 2025. Net profit was negative across reported quarters, with -Rs 0.43 Cr in Jun 2025, -Rs 0.39 Cr in Sept 2025, and -Rs 0.37 Cr in Dec 2025.
Profitability & Returns
The company's profitability metrics are negative, with a profit margin of -825%. The return on equity (ROE) is -19.73%, and the return on capital employed (ROCE) is -2.32%. Earnings per share (EPS) is 0.
Balance Sheet
Transgene Biotek Ltd. has a book value of Rs 1.11 per share. The debt-to-equity ratio is 1.38, indicating that the company uses a significant amount of debt relative to its equity.
Ownership & Pledges
The public shareholding is 76.3627%. There are no pledged shares by the promoters.
Regulatory & Surveillance
The company is currently under GSM (Graded Surveillance Measure) Stage 0.
Data as of — price: 2026-10-30 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.